한빛사 논문
서울대학교분당병원
HE Lee1,2, MA Kim1,2, HS Lee2,3, E-J Jung2, H-K Yang4, BL Lee5, Y-J Bang6 and WH Kim*,1,2,5
1Department of Pathology, Seoul National University Hospital, 28 Yeongeon-dong, Jongno-gu, Seoul 110-799, Korea;
2Department of Pathology, Seoul National University College of Medicine, Seoul, Korea;
3Department of Pathology, Seoul National University Bundang Hospital, Seongnam, Korea;
4Department of Surgery, Seoul National University College of Medicine, Seoul, Korea;
5Cancer Research Institute, Seoul National University College of Medicine, Seoul, Korea;
6Department of Medicine, Seoul National University College of Medicine, Seoul, Korea
*Corresponding author
Abstract
Background:
The aim of this study was to compare gene copy number (GCN) and protein expression of MET and to evaluate their prognostic roles in gastric carcinomas.
Methods:
MET protein expression and gene amplification (GA) status were determined by immunohistochemistry (IHC) and silver in-situ hybridisation (SISH), respectively, in a large series of gastric carcinoma.
Results:
Protein overexpression was observed in 104 of 438 cases, with IHC 2+ in 94 and IHC 3+ in 10, and high polysomy of chromosome 7 and GA were found in 61 and 13 of 381, respectively. Direct comparison revealed a significant correlation between high level of protein expression and increased GCN. All cases with GA showed protein overexpression. Furthermore, all with IHC 3+ showed GA except 1, even which could be categorised as GA according to the ASCO/CAP guideline for human epidermal growth factor receptor 2 assessment. IHC 3+ and GA were significantly associated with poor prognosis.
Conclusion:
MET IHC reflects well on GA, and therefore, it could be a primary screening test for patient selection for anti-MET therapy if GA is a major determinant of drug responsiveness. Also, the prognostic role of MET indicates that anti-MET therapy is a very promising modality in adjuvant treatment for gastric cancer.
논문정보
관련 링크
연구자 키워드
연구자 ID
관련분야 연구자보기
소속기관 논문보기
관련분야 논문보기
해당논문 저자보기